BARDA Selects Pharm-Olam to Support Trial Planning & Execution
Pharm-Olam, a global mid-sized clinical research organization, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to join their Clinical Studies Network. Under the terms of the contract, Pharm-Olam will provide routine and/or response clinical services for the advanced development of medical countermeasures.
Pharm-Olam's contract with BARDA is an indefinite-delivery, indefinite-quantity or IDIQ agreement for Clinical Trial Planning and Execution or CTPE services with application possibilities encompassing Phases I-IV. The contract has a minimum performance period of two years, stretching to a maximum of five years, with a $250M total contract ceiling value.
To read the full release, click here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
